Annette Kubalek
Nurse Practitioner · Indiana, PANPI 1376089334
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 87.1% of it on its own, with 31 other manufacturers making up the rest. 2025 is the largest year on record at $43,799, more than ten times the $721 reported in 2021. Among nurse practitioner clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 416 payments — averaging $135.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$49K
- Ascensia Diabetes Care US Inc.$3K
- Bigfoot Biomedical Inc$825
- Tandem Diabetes Care, Inc.$551
- Amgen$326
- Lilly USA, LLC$326
- plus $2K from 26 others
What the payments were for
- Consulting fees$3,8907%
- Speaking & faculty fees$21,63838%
- Travel & lodging$3,9237%
- Food & beverage$26,91448%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 238 | $49,092 |
| Ascensia Diabetes Care US Inc. | 8 | $3,032 |
| Bigfoot Biomedical Inc | 8 | $825 |
| Tandem Diabetes Care, Inc. | 27 | $551 |
| Amgen(2 entities) | 9 | $326 |
| Lilly USA, LLC | 18 | $326 |
| Medtronic | 14 | $307 |
| Averitas Pharma Inc. | 13 | $233 |
| Mannkind Corporation | 7 | $225 |
| AstraZeneca(2 entities) | 10 | $203 |
| Bayer | 9 | $182 |
| Novo Nordisk | 9 | $139 |
| Dexcom, Inc. | 5 | $126 |
| Sanofi-aventis U.S. LLC | 6 | $110 |
| Cequr Corporation | 2 | $84 |
| Insulet Corporation | 5 | $84 |
| AbbVie | 4 | $70 |
| Ascendis Pharma Endocrinology Inc | 3 | $68 |
| GRT US Holding, Inc. | 4 | $67 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $45 |
| Neurocrine Biosciences, Inc. | 2 | $39 |
| Antares Pharma, Inc. | 2 | $38 |
| Radius Health, Inc. | 2 | $29 |
| Boston Scientific | 2 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Novartis | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $17 |
| Zealand Pharma US, Inc. | 1 | $16 |
| BETA Bionics, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $14 |
| Nevro Corp. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$47,557
- UNITY DIABETES MANAGEMENT SYSTEM$700
- TEPEZZA$146
- t-slim insulin pump$125
How this compares
$56,365 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 780 | $876,781 |
| TrulicityDulaglutide | 425 | $464,059 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 251 | $370,565 |
| JardianceEmpagliflozin | 367 | $307,948 |
| MounjaroTirzepatide | 240 | $247,544 |
| FarxigaDapagliflozin Propanediol | 218 | $165,219 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 165 | $134,414 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 175 | $131,817 |
| InvokanaCanagliflozin | 122 | $119,834 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 191 | $116,839 |
| Xigduo XrDapaglifloz Propaned/Metformin | 155 | $111,140 |
| RybelsusSemaglutide | 58 | $61,726 |
| FiaspInsulin Aspart (Niacinamide) | 51 | $60,898 |
| Tresiba Flextouch U-200Insulin Degludec | 64 | $57,009 |
| Tresiba Flextouch U-100Insulin Degludec | 102 | $55,280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Fiasp, Novolog | $139 | $1,393,0531,248 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $326 | $746,547830 claims |
| AstraZenecaFarxiga | $203 | $165,219218 claims |
| Johnson & JohnsonInvokana | $12 | $119,834122 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Admelog | $110 | $36,13355 claims |
| BayerKerendia | $182 | $29,85341 claims |
| Cequr CorporationCequr Simplicity | $84 | $12,35427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Indiana
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Tracey WileyChambersburg$101K
- Pamela LorditchJohnstown$81K
- Nana BernaskoHershey$81K
- Dawn JeanneratClarion$78K
- Carolyn GrandePhiladelphia$71K
- Nicole WaetzmanStrafford$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.